TRCT
CLRB icon

Tower Research Capital (TRC)’s Cellectar Biosciences CLRB Stock Holding History

Tower Research Capital (TRC)’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-793
Closed -$2.01K – 5267
2026
Q1 		$2.01K Sell
793
-1,040
-57% -$3.36K ﹤0.01% 4559
2025
Q4 		$5.41K Buy
1,833
+743
+68% +$2.74K ﹤0.01% 4128
2025
Q3 		$6.1K Buy
1,090
+895
+459% +$4.43K ﹤0.01% 4177
2025
Q2 		$1.39K Buy
+195
New +$1.71K ﹤0.01% 4820
2024
Q4 		– Sell
-76
Closed -$4.89K – 5723
2024
Q3 		$4.89K Sell
76
-985
-93% -$65K ﹤0.01% 4386
2024
Q2 		$79.6K Buy
1,061
+880
+486% +$84.4K ﹤0.01% 2752
2024
Q1 		$21.6K Buy
181
+58
+47% +$6.29K ﹤0.01% 2935
2023
Q4 		$10.2K Sell
123
-76
-38% -$5.66K ﹤0.01% 4278
2023
Q3 		$15.7K Buy
199
+38
+24% +$2.24K ﹤0.01% 3598
2023
Q2 		$9.44K Buy
161
+9
+6% +$433 ﹤0.01% 4280
2023
Q1 		$7K Sell
152
-108
-42% -$5.26K ﹤0.01% 4724
2022
Q4 		$13K Buy
260
+210
+420% +$12.6K ﹤0.01% 3587
2022
Q3 		$5K Sell
50
-5
-9% -$719 ﹤0.01% 5129
2022
Q2 		$7K Buy
55
+27
+96% +$3.86K ﹤0.01% 4772
2022
Q1 		$6K Buy
28
+25
+833% +$4.38K ﹤0.01% 4859
2021
Q4 		$0 Buy
+3
New +$722 ﹤0.01% 6175
2021
Q2 		– Sell
-51
Closed -$25K – 5509
2021
Q1 		$25K Buy
+51
New +$30.3K ﹤0.01% 3702
2020
Q4 		– Sell
-19
Closed -$7K – 5144
2020
Q3 		$7K Sell
19
-7
-27% -$2.77K ﹤0.01% 4224
2020
Q2 		$10K Buy
+26
New +$10.9K ﹤0.01% 4001
2016
Q4 		– Hold
0
– -$2K – 3867
2016
Q3 		– Hold
0
– – – 3040
2016
Q2 		– Hold
0
– – – 3669
2016
Q1 		– Hold
0
– – – 3064
2015
Q4 		– Hold
0
– – – 4533
2015
Q3 		– Hold
0
– – – 4075
2015
Q2 		– Hold
0
– -$3K – 4441
2015
Q1 		– Hold
0
– – – 3542
2014
Q4 		– Hold
0
– – – 3607
2014
Q3 		– Hold
0
– – – 4457

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Tower Research Capital (TRC)'s CLRB Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Cellectar Biosciences (CLRB) in Q2 2026, closing a stake of 793 shares — an estimated $2.01K sold.

Tower Research Capital (TRC) first reported a position in CLRB in Q2 2020 and held it in 19 quarters. The position peaked at $79.6K in Q2 2024. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Cellectar Biosciences position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 793 Cellectar Biosciences shares in Q2 2026, an estimated $2.01K.
  • Tower Research Capital (TRC) first reported a position in Cellectar Biosciences in Q2 2020 and held it in 19 quarters.
  • Tower Research Capital (TRC)'s Cellectar Biosciences position peaked at $79.6K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.